29-05-2025
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)
Clear Street analyst William Maughan reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $17.00. The company's shares closed today at $4.62.
Confident Investing Starts Here:
Maughan covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, Delcath Systems, and Summit Therapeutics. According to TipRanks, Maughan has an average return of 18.5% and a 49.37% success rate on recommended stocks.
In addition to Clear Street, Y-Mabs Therapeutics also received a Buy from H.C. Wainwright's Robert Burns in a report issued on May 19. However, on May 13, Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (NASDAQ: YMAB).
Based on Y-Mabs Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.9 million and a GAAP net loss of $5.2 million. In comparison, last year the company earned a revenue of $19.93 million and had a GAAP net loss of $6.63 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year. Most recently, in March 2025, Thomas Gad, the CBO of YMAB sold 10,810.00 shares for a total of $56,536.30.
